1st WG1 INFOGUT Community Webinar

1st WG1 INFOGUT Community Webinar

In vitro Colonic fermentation: hype or hope?

Speaker 1

Dr. Katia Sivieri Professor

Department of Food and Nutrition, Laboratory Study of Probiotics and Prebiotics, Faculty of PharmaceuticalSciences of Araraquara, UNESP-Paulista State University, Araraquara, Sâo Paulo, Brazil.

Abstract 1

In vitro colonic fermentation is a valuable tool for studying gut microbiota behavior and metabolite productionunder controlled conditions. While it offers important insights into diet— microbiota interactions, limitations such asthe lack of host—microbe interactions remain. This talk evaluates whether these models represent real promise orrequire cautious interpretation for predicting in vivo outcomes.

Speaker background 1

Dr. Katia Sivieri is an expert in gut microbiota, in vitro digestion and colonic fermentation models, with over 15years of research experience. Her work bridges basic and translational science, focusing on probiotics, prebiotics, bioactive compounds, and microbiota—host interactions. She has led numerous academic and industry-driven projects, contributing significantly to personalized nutrition and gut health research.

Title 2

Utilizing high-throughput in vitro human fecal fermentation models to identify dietary inhibitors of gut bacterialtrimethylamine production

Speaker 2

Dr. Andrew P. Neilson Professor

Plants for Human Health Institute, Department of Food, Nutrition and Bioprocessing Sciences, North CarolinaState University, Kannapolis, North Carolina, USA

Abstract 2

Elevated blood trimethylamine //-oxide (TMAO) levels are a risk factor for atherosclerosis development. The firststep in the TMAO pathway is release of trimethylamine (TMA) from dietary quaternary amines substrates by gutbacteria expressing TMA lyases. We have developed high-throughput human fecal fermentation models to studyinhibition of TMA production by dietary phenolics.

Speaker background 2

Dr. Neilson is a Professor at North Carolina State University. Dr. Neilson’s research focuses on interactions between dietary bioactives and the gut microbiome.. He is an associate editor for the journal Food & Function and a Fellow of the Royal Society of Chemistry (UK).

COST

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation. (www.cost.eu)

COST Action CA23110

Scientific literature is shedding light on the centrality of GI for human health and wellbeing. Indeed, the physiologic effects of nutrients, bioactives and even toxic compounds (including foodborne pathogens) are mediated by their absorption rate in the intestine and by their interaction with gut microbiota and its host ecosystem. Testing food, feed, supplements or drugs in clinical studies gives rise to ethical issues, and the transferability of animal data across species is often problematic because of differences in physiology, metabolism and chemical susceptibilities.

MoU
062/22

CSO Approval Date
27/05/2022

Start Date
06/10/2024

End Date
05/10/2028

2026 | Cost Action CA23110 | All Right Reserved  | Design by Onno Media